Research / RMR / Fundamental state Inspectable configuration
State dimensions Filing 0001644378-26-000007 General Corporate
Operating cash generation 54th Own-history percentile · N=13
Evidence method Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
16.11% · OPTIONAL · VALID
Revenue growth 100th Own-history percentile · N=9
Evidence method Yoy · gp.fundamentals.revenue
40.76% · CORE · VALID
Operating margin 100th Own-history percentile · N=13
Evidence method Level · gp.fundamentals.operating_margin
48.10% · CORE · VALID
SBC intensity 69th Own-history percentile · N=13
Evidence method Level · gp.fundamentals.sbc_revenue_ratio
2.93% · OPTIONAL · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 12 states History building
Sep 30, 2023 0/5 normalized Level 3 Dec 31, 2023 0/6 normalized Level 3 Mar 31, 2024 0/6 normalized Level 3 Jun 30, 2024 0/6 normalized Level 3 Sep 30, 2024 4/5 normalized Level 3 Dec 31, 2024 4/5 normalized Level 3 Mar 31, 2025 4/5 normalized Level 3 Jun 30, 2025 3/4 normalized Level 3 Sep 30, 2025 4/5 normalized Level 3 Dec 31, 2025 4/4 normalized Level 3 Mar 31, 2026 4/4 normalized Level 3 Jun 30, 2026 4/4 normalized Level 3 Period transition
What moved in the state? Cash Generation Decreased
Previous 41.46%
Current 16.11%
Delta -25.35% Growth Increased
Previous -5.78%
Current 40.76%
Delta 46.55% Profitability Increased
Previous 22.87%
Current 48.10%
Delta 25.23% Sbc Intensity Decreased
Previous 5.29%
Current 2.93%
Delta -2.36% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.